HTG EdgeSeq Technology Highlighted in Multiple Posters Presented by Pharma Partners at the 2020 American Association for Cancer Research Virtual Meeting
“We were pleased to see our technology highlighted in two additional abstracts at this year’s AACR virtual meeting,” said
Posters presented at the 2020 Virtual AACR meeting using HTG EdgeSeq technology include:
- Comparison of HTG-Edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies; and
- Pan-cancer gene expression analysis of tissue microarray using
HTG EdgeSeq Oncology Biomarker Paneland a cross-comparison with ERBB3 immunohistochemical analysis.
“These posters highlighting our technology at this year’s AACR conference are a testament to the utility of our technology,” said
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential impacts on our business of these publications. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including but not limited to, the risk that our technology does not perform as expected. These and other factors are described in greater detail in our filings with the
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.